Tag: KDC-MN-085

  • AOD-9604

    Modified hGH 176-191 fragment

    A modified C-terminal fragment of hGH (residues 176-191) developed for fat loss without GH metabolic effects.

    Abstract

    AOD-9604 (modified hGH 177-191; molecular formula C78H125N23O23S2) is a modified analog of the C-terminal fragment of human growth hormone (residues 176-191) developed by Monash University and Metabolic Pharmaceuticals. The structural modification is the addition of a tyrosine at the N-terminus relative to the unmodified 176-191 sequence. The compound was developed on the rationale that the lipolytic activity of human growth hormone resides in the C-terminal fragment, separable from the IGF-1-mediated growth-promoting and pro-diabetogenic activities. Phase 2 trials in obesity showed modest weight loss and fat mass reduction without effect on lean mass or insulin sensitivity. The compound did not advance to FDA approval; clinical efficacy was not strong enough to support marketing. The compound is sold as a research chemical/peptide.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.